Foreword
Every year, Evaluate’s World Preview report unveils a series of much-followed analyses of global biopharma prescription drug revenues. Amongst the usual top tens of companies, drugs, and pipelines that show where the industry is rising, is a view of patent expiries and the end of drug lifecycles. For some time, this chart has warned of a coming patent cliff of a scale not seen before. Between 2025 and 2030, brands with a cumulative $300bn of revenues will face loss of exclusivity and competition from lower cost generics and biosimilars.
Positively for patients and healthcare budgets, this represents a considerable cost saving opportunity – improving access to treatment and allowing reinvestment into the next generation of innovative therapies. But for pharma companies, there are significant challenges to manage their portfolios in such a way that bridges this patent cliff and provides continuous growth.
This year, to mark the eventual arrival of this patent cliff, Evaluate is diving deeper into the portfolio considerations that large pharmas are staring down. From the constituent expiries to the resulting growth gaps, each company is facing a unique set of circumstances. A well-crafted strategy is needed to mitigate the impact of this patent cliff, and this report finishes with a set of archetypes to emerge beyond 2030 in the strongest of health.
